11.2019

Ventac Partners portfolio company RhoVac announced that the first patient has been screened for the company's clinical phase IIb study in prostate cancer, a study entitled RhoVac-002 ("BRaVac"). For more information please follow this link.

by Ventac Partners

08.2019

Ventac Partners portfolio company RhoVac reports it has been granted 2.5 million euro from Horizon 2020. For more information, please follow this link.

by Ventac Partners

06.2019

Ventac Partners portfolio company Idogen reports it has successfully established a novel method for the company's cell therapy. For more information, please follow this link.

by Ventac Partners

06.2019

Ventac portfolio companies Coegin Pharma (formerly Avexxin) and APIM Therapeutics will be attending the BIO Annual Meeting in Philadelphia, USA.

by Ventac Partners

06.2019

Ventac Partners portfolio company RhoVac AB receives approval to start clinical phase IIb study in Denmark. For more information, please follow this link.

by Ventac Partners

07.2019

Ventac Partners portfolio company RhoVac reports positive results from the 12 months follow-up of the company’s phase I/II clinical study. For more information, please follow this link.

by Ventac Partners

04.2019

Ventac Partners portfolio company RhoVac announces that all patients completed the follow-up phase of the clinical phase I / II study. For more information, please follow this link.

by Ventac Partners

03.2019

Ventac portfolio companies Avexxin, APIM Therapeutics and RhoVac will be attending BioEurope Spring Partnering conference at Vienna, March 25-27.

by Ventac Partners

01.2019

Ventac Partners portfolio company, RhoVac, reports positive interim immune-results in the follow-up phase of company’s phase I/II clinical study. For more information, please follow this link.

by Ventac Partners